Clindamycin (7-chloro-7-deoxylincomycin-hydrochloride-monohydrate) is an antibiotic with a remarkable bacteriostatic and bactericidal activity against staphylococci [1, 4, 5, 8]. It may, therefore, be regarded as one of the drugs suited for therapy of staphylococcal osteomyelitis, especially after very good efficacy of Lincomycin was recorded in this disease. To confirm this assumption, however, the data on penetration of Clindamycin into the bone under conditions of routine clinical practice are needed above all. This study presents the preliminary results obtained in this respect.

Clindamycin exerts a remarkable inhibitory as well bactericidal activity against Staphylococcus aureus. The majority of strains are inhibited by concentrations attainable with normal dosage, and these concentrations are mostly adequate also in achieving a bactericidal effect. Very large inocula influence the bactericidal activity of clindamycin. To obtain complete bactericidal effect, a 6- to 8-hour exposure to MBC is generally necessary.

No abstract

The state of cell-mediated immunity was measured by the morphological method of lymphocyte transformation with and without PHA, in a group of 56 patients with bacterial infections and in a group of healthy controls. The patients were divided into three subgroups according to the aetiology: 1. Patients with Gram-positive infections, 2. Patients with Gram-negative infections, and 3. mixed infections. The transformation values with PHA were significantly (t-test) higher in the Gram-positive subgroups than in the control group. Transformation in cultures stimulated by PHA was much higher in the subgroup of patients with Gram-positive aetiology; the difference between the values in the Gram-negative and in the Gram-positive subgroups was also significant. A decrease of transformation value below 50% was observed in 6 out of 18 patients with Gram-negative aetiology, whereas in the Gram-positive group it was noted in only 2 out of 21 patients.

No abstract